Label: information for the patient
Kalydeco13.4mg powder for sachet
Kalydeco 25 mg powder for sachet
Kalydeco 50 mg powder for sachet
Kalydeco 59.5mg powder for sachet
Kalydeco 75 mg powder for sachet
ivacaftor
Read this label carefully before your child starts taking this medicine, as it contains important information for your child.
Kalydeco contains the active ingredient ivacaftor. Ivacaftor acts on the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a protein that forms a channel on the cell surface that allows particles such as chloride to enter and leave the cell. Due to mutations in the CFTR gene (see below), the movement of chloride is reduced in people with cystic fibrosis (CF). Ivacaftor helps certain abnormal CFTR proteins to open more frequently to improve the entry and exit of chloride from the cell.
Kalydeco granule is indicated:
Do not administer Kalydeco to your child
Warnings and precautions
Consult your child's doctor before starting Kalydeco.
Children
This medication should not be given to children under 4 months, as it is unknown ifivacaftoris safe and effective in these children.
This medication should not be given in combination withivacaftor/tezacaftor/elexacaftorto children under 2years, as it is unknown ifivacaftoris safe and effective in them.
Other medications and Kalydeco
Inform your child's doctor or pharmacist if your child is taking, has taken recently, or may need to take any other medication.Some medications may affect how Kalydeco works or increase the likelihood of side effects.Specifically, inform your child's doctor if your child is taking any of the following medications. The doctor may decide to adjust the dose or schedule more check-ups.
Taking Kalydeco with food and drinks
Avoid giving your child foods or drinks that contain grapefruit during treatment with Kalydeco, as they may increase the side effects of Kalydeco by increasing the amount of ivacaftor in your child's body.
Driving and operating machinery
Kalydeco may cause your child to feel dizzy. If your child feels dizzy, it is recommended thatthey not ride a bike or engage in any activity that requires their full attention.
Kalydeco contains lactose and sodium.
If your child's doctor has told you that your child has a certain sugar intolerance, consult with them before giving your child this medication.
Kalydeco contains less than1mmolof sodium(23mg) per dose; this is, essentially “sodium-free”.
Follow exactly the administration instructions of this medication indicated by your child's doctor. In case of doubt, consult your child's doctor again.
Your child's doctor will determine the correct dose for your child. Your child should continue using all other medications, unless your child's doctor advises them to stop taking one.
The dosing recommendations for Kalydeco are provided in Table 1.
Table1: Dosing Recommendations
Administer the morning granule dose and the evening granule dose to your child with a 12-hour difference.
If your child has liver problems, it may be necessary for your child's doctor to reduce the dose of Kalydeco, as your child's liver will not eliminate the medication from their body as quickly as in children with normal liver function.
Kalydeco should be taken orally.
Each packet is for single use only.
Administration of Kalydeco to your child:
Foods or snacks containing fats include those prepared with butter or oils or those containing eggs. Other foods containing fats are:
If your child takes more Kalydeco than they should
Your child may experience adverse effects, including those listed in section4 below. If so, consult your child's doctor or pharmacist. If possible, show them the medication and this leaflet.
If you forgot to give Kalydeco to your child
Give the missed dose if it has been less than 6hours since your child was supposed to take the dose. Otherwise, wait until the next scheduled dose is due. Do not give a double dose to make up for the missed dose.
If you interrupt treatment with Kalydeco for your child
Administer Kalydeco to your child for the entire time recommended by your child's doctor. Do not stop treatment unless your child's doctor advises you to. If you have any other questions about using this medication, ask your child's doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Severe side effects
Abdominal pain andincreased liver enzymes in the blood.
Possible signs of liver problems
The increase in liver enzymes in the blood is common in patients with FQ and has also been reported in patients taking Kalydeco alone or in combination with ivacaftor/tezacaftor/elexacaftor.
In patients taking Kalydeco in combination with ivacaftor/tezacaftor/elexacaftor,liver damage and worsening of liver functionhave been reported in people with severe liver disease.The worsening of liver function can be severe and may require a transplant.
The following may be signs of liver problems:
Depression
The signs of depression include a sad or altered mood, anxiety, or emotional discomfort.
Inform your child's doctor immediately if your child experiences any of these side effects.
Side effectsvery common(can affect more than1 in 10people)
Side effectscommon(can affect up to1 in 10people)
Side effectsuncommon(can affect up to1 in 100people)
Unknown frequency(cannot be estimated from available data)
Additional side effects in children and adolescents
The side effects observed in children and adolescents are similar to those observed in adults. However, increased liver enzymes in the blood are more common in young children.
Reporting side effects
If your child experiencesany typeof side effect, consult your child's doctor or pharmacist, even if it is a side effect that does not appear in this leaflet.You can also report them directly through thenational notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears onthe box, the container, and the envelopeafter CAD/EXP. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Once mixed, the mixture has been shown to be stable for one hour.
Medicines should not be thrown down the drain or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. In this way, you will help protect the environment.
Kalydeco Composition
Kalydeco 13.4mg granule in blister pack:
Each blister pack contains 13.4mg of ivacaftor.
Kalydeco 25mg granule in blister pack:
Each blister pack contains 25mg of ivacaftor.
Kalydeco 50mg granule in blister pack:
Each blister pack contains 50mg of ivacaftor.
Kalydeco 59.5mg granule in blister pack:
Each blister pack contains 59.5mg of ivacaftor.
Kalydeco 75mg granule in blister pack:
Each blister pack contains 75mg of ivacaftor.
The other components are:silica anhydrous, sodium croscarmellose, acetate succinate of hypromellose, lactose monohydrate, magnesium stearate, mannitol, sucralose and sodium lauryl sulfate (E487).
See the end of section2: Kalydeco contains lactose and sodium.
Appearance of the product and contents of the pack
Kalydeco 13.4 mg granule in blister pack is a white or off-white granule.
Kalydeco 25mg granule in blister pack is a white to off-white granule.
Kalydeco 50mg granule in blister pack is a white to off-white granule.
Kalydeco 59.5mg granule in blister pack is a white to off-white granule.
Kalydeco 75mg granule in blister pack is a white to off-white granule.
The granule is supplied in blister packs.
Kalydeco 25mg granule in blister packs, Kalydeco 50mg granule in blister packs and Kalydeco 75mg granule in blister packs:
Blister pack size of 56sheets (contains 4individual cartons with 14sheets each).
Kalydeco 59.5mg granule in blister packs:
Blister pack size of 28sheets (contains 4individual cartons with 7sheets each).
Marketing Authorization Holder
Vertex Pharmaceuticals (Ireland) Limited
Unit 49, Block 5, Northwood Court,Northwood Crescent
Dublin 9, D09 T665,
Ireland
Tel.: +353 (0)1 761 7299
Responsible Person
Almac Pharma Services (Ireland) Limited
Finnabair Industrial Estate
Dundalk
Co. Louth
A91 P9KD
Ireland
Almac Pharma Services Limited
Seagoe Industrial Estate
Craigavon
County Armagh
BT63 5UA
UK
For further information about this medicinal product, please contact the local representative of the marketing authorization holder:
|
Last update of the summary of product characteristics:
Other sources of information
The detailed information on this medicinal product is available on the website of the European Medicines Agency:http://www.ema.europa.eu.There are also links to other websites on rare diseases and orphan medicinal products.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.